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Abstract
Background: Disease flares are common in rheumatoid arthritis (RA) and are related to structural damage. However, few
data on the impact of flares reported by patients on radiographic progression are available. Our aim was to investigate
whether overall flares (OF), self-reported flares (SRF) and short flares assessed at the visit (SF) predict radiographic
progression in RA patients in DAS28 (28-joint disease activity score) remission.
Methods: We reviewed the records of RA patients included in our database. We considered all patients who had
a period of at least 24 months in remission (DAS28 < 2.6), stable biologic and synthetic disease-modifying anti-
rheumatic drug treatment, no missing follow-up visits and hands and feet radiographs at the start and at the end
of the 24-month follow up. Radiographic progression was considered as an increase in the van der Heijde modified total
Sharp score >0. Patients were assessed every 3 months and flares were recorded. We defined SRF as any worsening of
the disease reported by patients occurring in the time between visits and SF as an increase in DAS28 ≥ 2.6 or >0.6 from
the previous visit assessed by the physician in one isolated visit. The impact of SRF, SF and OF on radiographic
progression was assessed through multivariate regression analysis.
Results: One hundred forty-nine patients were included. The median number (interquartile range) of OF was 1.00/year
(0.50; 1.38), of SRF was 0.50/year (0.14; 1.00), and of SF was 0.34/year (0; 0.50). Eighteen patients (12.1 %) experienced a
progression of radiographic damage. OF and SRF were significant predictors of radiographic progression: OR 3.27, 95 %
CI 1.30, 8.22 and OR 3.63, 95 % CI 1.16, 11.36, respectively.
Conclusions: OF and SRF are predictors of structural damage. Flares assessed at the visit, SF, do not impact on
radiographic progression as they might underestimate the actual number of flares.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease leading to joint disruption and eventually, disability.
Treatment with biologic drugs has made clinical remis-
sion an achievable target. Nevertheless, periodic fluctua-
tions of disease activity are common in RA [1] and
occur also in patients in remission [2].
Although several efforts have been undertaken by inter-
national initiatives, no validated definition of flare is avail-
able. The Outcome Measures in Rheumatology Clinical
Trials group has recently proposed a core domain set to
measure RA flare [3], and the French Strategy of Treat-
ment in Patients with Rheumatoid Arthritis Group has
developed a patient self-assessed questionnaire, FLARE, to
identify fluctuations of disease activity that occur in the
time between visits [4].
Some considerable interest has arisen on what impact
flares have on the success of the treatment and on struc-
tural damage. Temporary variations in disease activity
have already been related to radiographic evidence of
progression [5–7] and disease flares at the time of the
visit are proved to be associated with disability [6, 7].
To date there is limited knowledge about flares re-
ported by patients and no information on the impact of
these flares on structural damage. The frequency and
duration of flares reported by patients have been investi-
gated in an observational study by means of a question-
naire: 99 % of patients, including those in remission,
reported flares in the 6 months before the visit over
3 years of follow up [8].
The aim of our study was to investigate whether flares
predict radiographic evidence of progression in RA pa-
tients in 28-joint disease activity score (DAS28) remis-
sion, examining flares reported by patients, self-reported
flares (SRF), and short flares (SF) defined according to
the DAS28 at the time of the visit.
Methods
Patients
We conducted a retrospective observational study in the
outpatient clinic of the Rheumatology Unit of Padova
University Hospital. All participants provided written in-
formed consent before inclusion in the study. The study
was carried out in accordance with the ethical standards
of the Declaration of Helsinki (1983) and was approved
by the Ethics Committee for the clinical trials of the
province of Padova.
All patients had a diagnosis of RA according to the
American College of Rheumatology 1987 classification
criteria [9] and had started treatment with a subcuta-
neous anti-tumour necrosis factor α agent between
January 2009 and October 2012. We reviewed the clin-
ical records of our patients and we included in the
study those who had had a period of at least 24 months
in remission and stable biologic and disease-modifying
anti-rheumatic drug (DMARD) treatment.
Remission was defined as a DAS28 < 2.6, calculated
using C-reactive protein (CRP) [10]. Patients who were
out of remission on one isolated visit (DAS28 ≥ 2.6)
within the 24-month period were maintained in the
study; patients with a DAS28 ≥ 2.6 on two consecutive
visits were excluded.
We considered patients on full-dose and on low-dose
biologic treatment. In our clinical practice, patients who
maintained remission for at least 6 months on a full-dose
biologic drug underwent dose reduction and continued on
low dose until remission was maintained. To ensure
homogeneous follow-up and treatment strategies, only pa-
tients on adalimumab (ADA) and etanercept (ETA) were
included. Full-dose treatments were ETA 25 mg twice
weekly and ADA 40 mg every 2 weeks; low-dose treat-
ments were ETA 25 mg weekly and ADA 40 mg every
3 weeks.
Concomitant DMARDs were methotrexate (MTX) (10–
15 mg weekly) or leflunomide (LFN) (10–20 mg daily).
Prednisone (PDN) could be used at a dose of ≤5 mg daily.
Data collected were: age, sex, disease duration at the
start of the current biologic treatment, seropositivity (posi-
tive anti-citrullinated peptides or positive rheumatoid fac-
tor), smoking status, previous anti-TNFα treatments and
biologic, DMARD and corticosteroid dose. Patients were
treated with a treat-to-target strategy and assessed every
3 months. At each follow-up visit, the DAS28 and the
Health Assessment Questionnaire (HAQ) were recorded.
Radiographs of the hands and feet were performed
every year in clinical practice. We collected radiographs
at the start and at the end of the 24-month follow up
and the van der Heijde modified total Sharp score (TSS)
was calculated by one radiologist. Mean TSS progression
per year before baseline was also calculated. Radio-
graphic progression was considered as evidence of an in-
crease in the TSS >0 at the 24-month follow up.
Flares
Flares were classified as SRF and SF. SRF were defined as
any worsening of the disease reported by patients, occur-
ring in the time between visits. At every follow-up visit pa-
tients were asked if they had experienced a worsening of
the symptoms related to RA. Any symptom attributed by
the patient to RA (i.e., joint pain, joint swelling, stiffness
and constitutional symptoms) was considered. SF were de-
fined according to the DAS28, being a DAS28 ≥ 2.6 or an
increase in the DAS28 > 0.6 from the previous visit
assessed by the physician at one isolated visit. The opinion
of the patient on whether he or she was experiencing a
flare at the time of the visit was not collected because this
was obtained in an assessment of the patient’s global
health measured on a visual analog scale (patient-VAS) as
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part of the DAS28. Flare duration (as reported by the
patient at the following visit), symptoms and treatment
changes were recorded. OF was defined as the sum of SF
and SRF.
Exclusion criteria were: missing follow-up visits, missing
radiographs or missing data during the 24-month follow
up; concomitant musculoskeletal conditions (e.g., fibro-
myalgia, osteoarthritis) and unreliability in reporting flares
(i.e., patients with cognitive impairment or lack of profi-
ciency in the Italian language).
Statistical analysis
Data are presented in all patients and according to the
occurrence of radiographic progression at the 24-month
follow up. Normal distributions of continuous variables
were tested using the Shapiro-Wilk test and, if normality
was satisfied, the data were shown as means ± standard
deviations (SD) and compared using the unpaired t test.
Variables with a non-normal distribution were presented
as medians with the corresponding interquartile range
(IQR) and compared using the Mann-Whitney test. Quan-
titative measures were compared using t chi-square test or
Fisher’s exact test. Flares are presented as the mean num-
ber of flares per year.
Multivariate analysis was run to assess the potential of
the numbers of OF, SRF and SF (independent variables)
to predict radiographic progression (dependent variable).
The impact of OF (model I), SRF (model II) and SF
number (model III) was assessed separately. The predic-
tors included in the final model were all variables with a
p-value <0.20 in the univariate analyses as reported in
Additional file 1: Table S1.
Collinearity was assessed by the variance inflation factor
(VIF), adopting a cut off of VIF = 2 as an exclusion criter-
ion. Variables excluded from the multivariate analysis
because of collinearity were the same in the three models:
HAQ at 24 months collinear with baseline HAQ (model I
VIF = 13.34, model II VIF = 12.77; model III VIF = 13.38)
and patient-VAS at 24 months collinear with change in
the patient-VAS at 24 months (model I VIF = 3.08, model
II VIF = 2.98, model III VIF = 3.01). The results of univari-
ate and multivariate logistic regression analysis are pre-
sented as the odds ratio (OR) with the corresponding
95 % confidence interval (CI). All analyses were performed
using SPSS version 22.0.
Results
Among 435 patients who started ADA or ETA, 323 fulfilled
the inclusion criteria, i.e., they had a period of 24 months in
remission, and stable biologic and DMARD treatment. One
hundred thirty-seven patients were excluded because of
missing follow-up visits, missing radiographs or missing
data during the 24-month follow up. Thirty-seven patients
were excluded because of concomitant musculoskeletal
comorbidities (7 patients with fibromyalgia and 9 with
osteoarthritis) or because they were not reliable in reporting
flares (13 with cognitive impairment and 3 patients with
lack of proficiency in the Italian language), leaving 149
patients (56 on ADA and 93 on ETA) eligible for the ana-
lysis. The characteristics of patients and treatments at base-
line are reported in Table 1. HAQ, DAS28 and DAS28
components at baseline and at the 24-month follow up are
also detailed.
There were 46 patients (30.9 %) on full-dose biologic
agents and 103 (69.1 %) on low-dose agents, with 34
(60.7 %) on low-dose ADA and 69 (74.2 %) on low-dose
ETA. A concomitant DMARD was used by 51 % of pa-
tients, with 50 patients on MTX and 26 on LFN. The
median PDN daily dose was 1 mg daily (0.74; 2.00). At
baseline median DAS28 was 2.21 (1.92; 2.38) and mean
HAQ score was 0.75 ± 0.32; the DAS28 and HAQ score
were stable over the 24-month follow up (Table 1).
In the 149 patients included in the study, there were
288 OF, 184 SRF, and 104 SF recorded over the 24-
month follow up; 25 patients experienced no flares.
The median number of OF was 1.00/year (0.50; 1.38),
of SRF was 0.50/year (0.14; 1.00), and of SF was 0.34/
year (0; 0.50) (Table 2). The mean duration of OF, as re-
ported by the patients, was 12.59 ± 5.36 days (12.87 ±
5.49 for SRF and 13.04 ± 5.16 for SF, p = 0.77). No pa-
tients experienced flares lasting more than 30 days.
Among patients with SRF, 84.8 % (156/184) reported
joint swelling or tenderness, 65.8 % (123/187) reported
stiffness, and 40.6 % (76/187) reported constitutional
symptoms (i.e., fatigue or fever).
Temporary changes (lasting ≤30 days) in treatment
were undertaken in most patients during flares; this was
so in 266/288 patients (92.4 %) with OF, 172/184 pa-
tients (93.5 %) with SRF and 94/104 patients (90.4 %)
with SF, p = 0.34. PDN dose was increased (up to 10 mg/
day) in 173/288 patients (60.1 %) with OF, 115/184 pa-
tients (62.5 %) with SRF and 58/104 patients (55.8 %)
with SF, p = 0.26. Non-steroidal anti-inflammatory drugs
(NSAIDs) were used in 168/288 patients (58.3 %) with
OF, 101/184 patients (54.9 %) with SRF and 67/104 pa-
tients (64.4 %) with SF, p = 0.11; intra-articular injections
were used in 7/288 patients (2.4 %) with SF. The median
DAS28 at the time of the flare in patients with SF was
3.22 (3.01; 3.87). On analysis of correlation between
patient-VAS at the end of follow up and the number of
OF the R value was 0.35, p < 0.01; for correlation be-
tween patient-VAS and the number of SRF the R value
was 0.34, p < 0.01.
Radiographic progression
There were 18 patients (12.1 %) with radiographic evi-
dence of progression of damage (TSS >0) at the 24-
month follow up; the median change in the TSS was 2,
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ranging from 1 to 14. Clinical variables and treatments
taken by patients according to radiographic progression
are reported in Table 1. The baseline HAQ score was
higher in patients who had structural damage compared
with those who did not (0.87 ± 0.25 and 0.73 ± 0.41, re-
spectively, p = 0.05) and there was also a trend towards a
higher HAQ score in these patients at the end of the 24-
month follow up (Table 1). Progression in the TSS per
year before baseline was significantly higher in patients
who experienced radiographic progression compared
with those who did not, with 10.25 (7.38; 15.50) vs 7.32
(5.00; 11.10), p = 0.02. Patient-VAS at the 24-month
Table 1 Demographics and clinical variables according to radiographic progression at the 24-month follow up
All patients No radiographic progression Radiographic progression P valuea
Number 149 131 18
Age, years, mean (SD) 58.15 (12.58) 57.60 (12.71) 62.22 (11.01) 0.11
Female, n (%) 123 (82.6) 108 (82.4) 15 (83.3) 0.61
Disease duration, years, median (IQR) 13.00 (8.00; 21.00) 13.00 (8.00; 20.50) 13.50 (8.50; 30.75) 0.41
Previous anti-TNFα failures, n (%) 30 (20.1) 26 (19.9) 4 (22.2) 0.51
Positive ACPA and/or RF, n (%) 76 (51.0) 65 (49.6) 11 (61.1) 0.36
Smokers or ex-smokers, n (%) 39 (26.2) 35 (26.7) 4 (22.2) 0.47
TSS progression per year before baseline, median (IQR) 8.00 (5.00; 11.63) 7.32 (5.00; 11.10) 10.25 (7.38; 15.50) 0.02
ADA treatments, n (%) 56 (37.6) 48 (36.6) 8 (44.4) 0.59
ETA treatments, n (%) 93 (62.4) 83 (63.4) 10 (55.6) 0.59
Low dose biologic, n (%) 103 (69.1) 89 (67.9) 14 (77.8) 0.40
Concurrent DMARD use, n (%) 76 (51.0) 66 (50.4) 10 (55.6) 0.68
PDN daily dose, mg, median (IQR) 1.00 (0.74; 2.00) 1.00 (0.60; 2.00) 1.50 (0.75; 2.00) 0.99
TSS progression at the 24-month follow up, median (IQR) 0 (0) 0 (0) 2.00 (2.00; 14.00) <0.01
Baseline
HAQ, mean (SD) 0.74 (0.40) 0.73 (0.41) 0.87 (0.25) 0.08
DAS28, median (IQR) 2.21 (1.92; 2.38) 2.24 (1.85; 2.38) 2.05 (2.05; 2.38) 0.53
CRP, mg/L, median (IQR) 3.00 (1.00; 4.00) 3.00 (1.00; 4.00) 1.00 (1.00; 4.00) 0.24
TJC, median (IQR) 1 (0; 2) 1 (0; 2) 1 (1; 1) 0.70
SJC, median (IQR) 0 (0) 0 (0) 0 (0) –
Patient-VAS, mm, median (IQR) 20 (15; 20) 20 (10; 30) 20 (0) 0.23
Follow up, 24 months
HAQ, median (IQR) 0.74 (0.39) 0.73 (0.40) 0.85 (0.23) 0.18
DAS28, median (IQR) 2.16 (1.80; 2.43) 2.18 (1.80; 2.63) 1.85 (1.82; 2.42) 0.52
CRP, mg/L, median (IQR) 2.00 (1.00; 3.00) 2.00 (1.00; 3.00) 2.00 (2.00; 3.00) 0.29
TJC, median (IQR) 1 (0; 2) 1 (0; 2) 0 (0; 1) 0.24
SJC, median (IQR) 0 (0) 0 (0) 0 (0) –
Patient-VAS, mm, median (IQR) 20 (10; 30) 20 (10; 30) 33 (28; 35) 0.01
Change between baseline and 24-month follow up
HAQ, median (IQR) 0 (−0.10; 0.07) 0 (−0.11; 0.07) 0.01 (−0.05; 0.05) 0.56
DAS28, mean (SD) −0.13 (0.55) 0 (0.58) −0.02 (0.30) 0.63
CRP, mg/L, median (IQR) 0 (−2.00; −2.00) 0 (−3.00; 2.00) 1.00 (−1.00; 1.00) 0.11
TJC, median (IQR) 0 (−1; −1) 0 (−1; −1) −1 (−1; 0) 0.28
SJC, median (IQR) 0 (0) 0 (0) 0 (0) –
Patient-VAS, mm, median (IQR) 5 (−5; 10) 0 (−10; 10) 13 (9; 15) <0.01
SD standard deviation, IQR interquartile range, TNFα tumor necrosis factor-α, ACPA anti-citrullinated peptides, RF rheumatoid factor, TSS total Sharp score, ADA
adalimumab, ETA etanercept, DMARD disease-modifying anti-rheumatic drug, PDN prednisone, HAQ Health Assessment Questionnaire, DAS28 disease activity score
in 28 joints, CRP C-reactive protein, TJC tender joint count in 28 joints, SJC swollen joint count in 28 joints, patient-VAS patient’s global health measured on a visual
analog scale. aUnpaired t test was used to compare variables with a normal distribution, Mann-Whitney test was used to compare variables with a non-normal
distribution. Quantitative measures were compared using the chi-square test or Fisher’s exact test
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follow up was significantly higher in those with radio-
graphic progression; likewise, the change in patient-VAS
from baseline to the 24-month follow up was higher in
the latter group, with 13 (9; 15) vs 0 (−10; 10), < 0.01
(Table 1).
The numbers of OF and SRF were significantly higher
in patients with radiographic progression compared with
those without radiographic progression, with 1.50 (1.00;
1.50) vs 0.98 (0.50; 1.00), p < 0.01 and 1.00 (0.50; 1.00) vs
0.50 (0.10; 1.00), p = 0.01, for OF and SF, respectively
(Table 2). The number of SF was also higher in patients
with radiographic progression, although not significantly,
with 0.50 (0.24; 0.63) vs 0.24 (0; 0.50), p = 0.08 (Table 2).
The predictors of radiographic progression were
tested by univariate regression analysis (Additional file 1:
Table S1) and accordingly, covariates were selected for
multivariate regression models. OF and SRF were inde-
pendent predictors of radiographic progression in model I
and II, respectively (Table 3), with OR of 3.27, 95 % CI
1.30, 8.22, p = 0.01 and 3.63, 95 % CI 1.16, 11.36, p = 0.03;
whereas SF were not significant predictors of radiographic
progression (OR 2.78, 95 % CI 0.70, 11.10, p = 0.15). In all
three regression models, a unit increase in the baseline
HAQ increased radiographic progression five-fold and
patient-VAS change two-fold (Table 3). A higher TSS for
progression per year before baseline was also an
independent predictor of radiographic progression in all
models (Table 3).
Discussion
Our study investigates the impact of flares on structural
damage in a clinical practice setting. Disease relapses at
the time of the visit have already been found to be asso-
ciated with radiographic progression [5–7], but to the
best of our knowledge this is the first study that specific-
ally considers flares reported by patients.
Previous studies proving the association between dis-
ease fluctuations and structural damage included pa-
tients with higher disease activity and adopted different
definitions of flare. Welsing et al. [5] considered disease
fluctuations as the standard deviation of the mean
changes in the DAS (in 44 joints); Lillegraven et al. [6]
considered the number of visits in remission and Mar-
kusse et al. [7] defined flares according to a DAS ≥2.4,
which corresponds to moderate disease activity.
In our study, the flare definition included two different
approaches, one objective definition based on the DAS28,
the other relying on patient experience. Flares reported by
patients, SRF, were found to independently predict radio-
graphic progression; by contrast, flares assessed by the
physician at the visit, SF, did not.
Table 2 Numbers of flares according to radiographic evidence of progression at 24-month follow up
All patients No radiographic progression Radiographic progression P valuea
Number 149 131 18
OF, number/year, median (IQR) 1.00 (0.50; 1.38) 0.98 (0.50; 1.00) 1.50 (1.00; 1.50) <0.01
SRF, number/year, median (IQR) 0.50 (0.14; 1.00) 0.50 (0.10; 1.00) 1.00 (0.50; 1.00) 0.01
SF, number/year, median (IQR) 0.34 (0; 0.50) 0.24 (0; 0.50) 0.50 (0.24; 0.63) 0.08
IQR interquartile range, OF overall flares, SRF self-reported flares, SF short flares. aThe Mann-Whitney test was used to calculate p values
Table 3 Risk of radiographic progression: multivariate regression analysis
Model I Model II Model III
Overall flares Self-reported flares Short flares
OR (95 % CI) P value OR (95 % CI) P value OR (95 % CI) P value
Number 149 149 149
Age (per 10-year increase) 1.10 (0.67, 1.82) 0.70 1.16 (0.71, 1.89) 0.55 1.09 (0.67, 1.78) 0.72
TSS progression per year before baseline (per unit) 1.12 (1.03, 1.23) 0.01 1.02 (1.02, 1.21) 0.02 1.10 (1.01, 1.20) 0.02
Baseline HAQ (per unit) 5.32 (1.05, 26.99) 0.04 5.07 (1.08, 23.79) 0.04 4.66 (0.98, 22.25) 0.05
CRP change at 24 months (per increasing quartile) 1.60 (0.87, 2.92) 0.13 1.66 (0.92, 3.01) 0.09 1.65 (0.92, 2.97) 0.09
Patient-VAS change at 24 months (per 10-unit increase) 2.08 (1.14, 3.81) 0.02 2.06 (1.14, 3.72) 0.02 2.28 (1.29, 4.01) 0.04
OF (per unit) 3.27 (1.30, 8.22) 0.01 – – – –
SRF (per unit) – – 3.63 (1.16, 11.36) 0.03 – –
SF (per unit) – – – – 2.78 (0.70, 11.10) 0.15
OF overall flares, SRF self-reported flares, SF short flares, TSS total Sharp score, HAQ health assessment questionnaire, CRP C-reactive protein, Patient-VAS patient’s
global health measured on a visual analog scale
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We defined SF according to the DAS28. The most dis-
criminating and valid DAS28-based definition of flare
has already been reported as an increase in DAS28 > 1.2
or >0.6 only if the current DAS28 is ≥3.2 [11]. We
deemed this criterion not suitable for patients in remis-
sion, as it does not take into account the loss of remis-
sion, i.e., DAS28 ≥ 2.6. On the other hand, defining flare
just as the loss of remission was shown to be non-
specific [11]. To increase the sensitivity in the detection
of mild worsening of disease activity, we also considered
a change in the DAS28 > 0.6 from the previous visit as a
criterion for SF, which is the DAS28 threshold in the re-
sponse criteria of the European League Against Rheuma-
tism (EULAR) [12].
SRF was defined as the worsening of any symptom at-
tributed to RA by the patient, and no threshold for dur-
ation of symptoms or symptom severity was required.
Although patients often describe a wide range of symp-
toms that are sometimes not related to RA in consult-
ation with the rheumatologist [13], it has been shown
that symptoms reported by patients with RA can com-
plement the physician’s opinion, especially for systemic
manifestations [14]. This study proves that the opinion
of patients is needed to fully assess disease activity, as pa-
tients can identify significant worsening of it. SRF are also
affected by memory bias. We chose a 3-month interval for
recalling flares, as it has been suggested as the optimum
time interval for detecting them [4] and it is a suitable
interval in the follow up of RA. Despite the fact that this
definition of SRF may be regarded as flawed, in our study
SRF were independently associated with structural dam-
age, supporting the evidence that patients can identify
relevant disease relapses and active synovitis.
No differences were observed in the duration of SF
and SRF, or in treatment administered. The greater im-
pact of SRF on structural damage was probably due to a
better estimate of the number of flares provided by SRF
compared with SF. In fact, SF are identified on clinical
assessment in one single visit and might underestimate
disease activity over time.
A higher mean TSS progression per year before base-
line and a higher HAQ at baseline were found to be pre-
dictors of radiographic progression. These indices are
markers of a more severe and erosive arthritis thus con-
ceiving the idea that disease severity is more likely asso-
ciated with persistent disease activity and consequently
with structural damage. An increase in patient-VAS over
the study period was also significantly associated with
radiographic evidence of disease progression, but it is
probably associated with frequent relapses experienced
by the patient rather than radiographic progression.
Treatment does not affect structural damage or the
number of flares. No differences were observed in the
number of SF, SRF or OF in relation to low- or full-dose
biologic agents, or to concomitant DMARD treatment.
This result is consistent with the treat-to-target treat-
ment strategy and endorses the observation that the dis-
ease can be fully controlled, even on low-dose biologic
agents, if patients are closely assessed [15]. This study
provides further evidence that flares are common in RA
patients even those in DAS28 remission [2]: considering SF
and SRF together, patients had a median of 1 flare per year
and SRF were almost two-fold more frequent than SF.
Although our study was limited to patients in remis-
sion and the definition of flare was different to defini-
tions proposed by other authors, the overall number of
flares that we observed was higher than reported in
other studies [7, 16, 17]. Also, SRF appear to be more
frequent compared with a previous study by Bykerk on
flares reported by patients: 30 % of patients in remission
reported ≥1 flare in the 6 months before the visit over a
3-year follow up compared with 83.2 % (124/149) of our
patients, who reported ≥1 flare in the 3 months before
the visit over a 2-year follow up [8]. This difference
could be partly explained by more recall bias in the
study by Bykerk, in which data on flares were collected
every 6 months rather than every 3 months as in our
study. Further, while we questioned patients at the time
of the visit about flares, patients in the study by Bykerk
were administered a questionnaire, which might have re-
duced patient compliance in providing the required in-
formation [8].
The major limitation of the study is its retrospective
nature; a prospective study could improve the detection
of flares, especially of SRF, through training patients to
better identify the flares and symptoms that are associ-
ated with structural damage. Another limitation of our
analysis is the small number of patients who achieved
the outcome: only 12.1 % (18/149) of patients had radio-
graphic evidence of disease progression, despite our def-
inition of progression being a change in the TSS >0,
instead of >0.5 as in previous studies [5–7]. This result
was largely expected because the study was aimed at iden-
tifying inadequate disease control and minimal structural
damage in patients in DAS28 remission during treatment
with biologic agents. Nevertheless, OF and SRF proved to
be strongly associated with radiographic progression (p =
0.01 and 0.03, respectively). Further, as there are no avail-
able validated definitions of patient-reported flares or of
flares in patients in remission, the definitions we adopted
were based on previous studies.
On the other hand, our study has some strengths as it
was conducted in a monocentric cohort of patients with
RA, which results in high homogeneity of the data col-
lected, clinical assessments and treatment decisions. Fur-
ther, a complete follow up of our patients was ensured by
the fact that in our country, follow-up visits are mandatory
for the prescription of the biological treatment.
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Conclusions
Flares are a common experience in patients with RA
who are in DAS28 remission, and most of the flares are
SRF occurring in the time between visits. OF and SRF
impact on structural damage in patients with RA in
DAS28 remission; by contrast, SF, assessed at the visit,
do not, as they underestimate the actual number of
flares. A definition of flare with thresholds for meaning-
ful changes in RA symptoms is needed, in order to iden-
tify patients prone to developing structural damage, who
might benefit from a treatment change despite their
apparent remission state.
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